LEO Pharma presented new data on delgocitinib cream at EADV 2026, with the company highlighting real-world outcomes in adults plus new adolescent data in chronic hand eczema (CHE).

The announcement, distributed via Ritzau, positions the presentations around two distinct evidence streams: real-world outcomes in adult patients and previously unseen adolescent data in CHE. Both address a therapeutic area where topical treatment options have long been limited.

What did LEO Pharma present?

The company framed the EADV 2026 contributions around delgocitinib cream, its topical pan-JAK inhibitor developed for chronic hand eczema. Two data sets anchored the presentation:

• Real-world outcomes in adults — evidence generated outside controlled trial conditions, reflecting how the cream performs in routine clinical practice.
• New adolescent data in CHE — findings extending the evidence base into a younger patient population.

Chronic hand eczema is one of the most common dermatological conditions affecting the hands, and it carries substantial functional and occupational burden. Real-world evidence matters in this indication because trial populations rarely capture the full diversity of patients clinicians actually treat.

Why does the adolescent angle matter?

Extending data into adolescents signals a broadening of the delgocitinib evidence base beyond the adult population in which the cream was studied initially. For dermatologists, pediatric and adolescent CHE has historically lacked dedicated topical treatment data, leaving clinicians to extrapolate from adult studies.

New adolescent findings, presented at a major European dermatology congress, give prescribers population-specific information rather than extrapolation. The specific endpoints and effect sizes from the adolescent data set were not detailed in the announcement.

What about the real-world adult data?

Real-world outcomes complement randomized controlled trials by showing effectiveness, tolerability and persistence of use in everyday practice — populations that include patients with comorbidities, occupational exposures and variable adherence often excluded from pivotal studies.

LEO Pharma's decision to foreground this evidence class at EADV 2026 suggests the company is building the practical case for delgocitinib cream alongside its registrational program. Again, the announcement did not specify numerical outcomes from the real-world analyses.

The road ahead

Dermatologists should expect fuller detail — patient numbers, endpoints such as IGA or CHE severity scores, and durability of response — as the EADV 2026 presentations are published in peer-reviewed journals, which will clarify where delgocitinib cream sits in the chronic hand eczema treatment algorithm for both adults and adolescents.